Alnylam Pharmaceuticals, based in Cambridge, Mass., has so far spent 15 years developing patisiran, an investigational RNAi drug for hATTR — and this past November, at a scientific meeting in Europe, the company presented Phase 3 trial results that appeared to blow the research community away. (fortune.com)
Although the sensory characteristics of the tone remain the same — its pitch, timbre and intensity — there is an indefinable and elusive change due to the simple fact that it endures... [I] ts present phase differs from its antecedent phase by the mere fact of being older. (religion-online.org)
Dr. Blagburn also recently helped present phase 2 of a groundbreaking study by John McCall, MS, PhD, at the 2016 AVMA convention in San Antonio. (goodnewsforpets.com)